Abstract: Dentifrice compositions comprising water, bicarbonate salt, and glycine or a salt thereof are effective in treating dental plaque biofilm. A dentifrice composition may include from about 15% to about 55%, by weight of the composition, of water, from about 20% to about 40% by weight of the composition, of sodium bicarbonate, from about 0.05% to about 5%, by weight of the composition, of neutral amino acid, where the neutral amino acid comprises glycine or a salt thereof, and from about 0.0025% to about 2%, by weight of the composition, of fluoride.

Abstract: The present invention relates to a preparation and purification method for cationic quaternary ammonium salt of sodium hyaluronate in homogeneous medium. By adding a homogeneous solvent and a sodium hyaluronate solid to a vessel, heating the vessel until the contents are dissolved to form a homogeneous system, adding an aqueous solution of 2,3-epoxypropyltrimethylammonium chloride (GTA) to the homogeneous system, then adding a base catalyst, and stirring at a preset temperature to carry out a graft reaction, a graft product is obtained wherein 2,3-epoxypropyltrimethylammonium chloride is grafted to the oxygen atom of the hydroxymethyl group of sodium hyaluronate. By using the method, a graft product wherein 2,3-epoxypropyltrimethylammonium chloride is grafted to the oxygen atom of the hydroxymethyl group of sodium hyaluronate is obtained. Addition of salts is avoided during the reaction, a grafting yield up to 0.69 is obtained, and coagulation occurred to the product is effectively solved.

Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Abstract: The present disclosure provides a method for controlling EGR rate of a low pressure EGR system, a system and a vehicle. The method calculates a molar concentration of water molecules of exhaust gas processed by EGR cooler, calculates a molar concentration of water molecules, obtains coefficient as to excess air, and calculates a molar volume ratio of air according to the coefficient. Under a maximum limit of humidity, an allowable EGR rate of the exhaust gas processed by the EGR cooler is determined and an allowable EGR rate of the mixed gas before entry into supercharger and/or compressor is also determined, a lower EGR rate between the two allowable rates is set as a maximum for application actual working conditions. The present disclosure solves a problem of condensation caused by an introduction of exhaust gas from the existing gasoline engine.

Abstract: The present invention discloses an N-alkyl-N-cyanoalkylbenzamide compound of General Formula I, an intermediate of General Formula II used to prepare the compound, wherein R1 is selected from halo or C1-C3 alkyl; R2 is selected from halo or CN; R3 is selected from halo, or C1-C3haloalkyl; R4 is selected from halo; R5 is selected from H or halo; R6 is selected from C1-C3alkyl, C1-C3 haloalkyl or C1-C5 alkoxyalkyl; R7 is selected from C1-C5 alkyl; and R8 is selected from hydrogen or C1-C5alkyl. Compared with the compounds in the prior art, the compound of General Formula I has a higher activity at a low concentration. Particularly, the compound of the present invention still has 60% or higher of the insecticidal activity at a concentration below 1 ppm. This greatly reduces the amount of the compound used and the residue of the compound in farmland, and is thus environmentally friendly.

Abstract: The present invention discloses a preparation method of an all-solid-state lithium battery based on borohydride/sulfide two-layer fast ion conductors, comprising the steps of: Step 1: cold-pressing a borohydride fast ion conductor and a sulfide fast ion conductor into a two-layer electrolyte; Step 2: mixing a cathode active material, a sulfide fast ion conductor, and a conductive agent according to a ratio to prepare a cathode of the all-solid-state lithium battery, and cold-pressing the cathode onto a side, corresponding to the sulfide fast ion conductor, of the two-layer electrolyte obtained in Step 1; and taking a lithium metal plate as an anode of the all-solid-state lithium battery, and cold-pressing the anode onto a side, corresponding to the borohydride fast ion conductor, of the two-layer electrolyte obtained in Step 1; and Step 3: packaging a material obtained in Step 2 to obtain the all-solid-state lithium battery based on borohydride/sulfide two-layer fast ion conductors.

Abstract: The present invention discloses a preparation method of an all-solid-state lithium battery based on borohydride/sulfide two-layer fast ion conductors, comprising the steps of: Step 1: cold-pressing a borohydride fast ion conductor and a sulfide fast ion conductor into a two-layer electrolyte; Step 2: mixing a cathode active material, a sulfide fast ion conductor, and a conductive agent according to a ratio to prepare a cathode of the all-solid-state lithium battery, and cold-pressing the cathode onto a side, corresponding to the sulfide fast ion conductor, of the two-layer electrolyte obtained in Step 1; and taking a lithium metal plate as an anode of the all-solid-state lithium battery, and cold-pressing the anode onto a side, corresponding to the borohydride fast ion conductor, of the two-layer electrolyte obtained in Step 1; and Step 3: packaging a material obtained in Step 2 to obtain the all-solid-state lithium battery based on borohydride/sulfide two-layer fast ion conductors.

Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Abstract: The present invention discloses an N-alkyl-N-cyanoalkylbenzamide compound of General Formula I, an intermediate of General Formula II used to prepare the compound, wherein R1 is selected from halo or C1-C3 alkyl; R2 is selected from halo or CN; R3 is selected from halo, or C1-C3haloalkyl; R4 is selected from halo; R5 is selected from H or halo; R6 is selected from C1-C3alkyl, C1-C3 haloalkyl or C1-C5 alkoxyalkyl; R7 is selected from C1-C5 alkyl; and R8 is selected from hydrogen or C1-C5alkyl. Compared with the compounds in the prior art, the compound of General Formula I has a higher activity at a low concentration. Particularly, the compound of the present invention still has 60% or higher of the insecticidal activity at a concentration below 1 ppm. This greatly reduces the amount of the compound used and the residue of the compound in farmland, and is thus environmentally friendly.

Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Abstract: The present invention discloses a pyrazolamide compound of General Formula I having an insecticidal activity and an intermediate of General Formula II used to preparing the compound of General Formula I, wherein R1 is selected from chloro or CN, R2 is selected from H, C1-C3 alkyl, C1-C3 haloalkyl or C1-C5 alkoxyalkyl, R3 is selected from halo or C1-C3 haloalkyl, R4 is selected from halo, and R5 is selected from H or halo. Compared with the compounds in the prior art, the compound of General Formula I of the present invention has a higher activity at a low concentration. This reduces the amount of the compound used and the residue of the compound in farmland, and is thus environmentally friendly.

Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.